References

1. Kogan I.Yu., Gerkulov D.A. Aktual’nye nauchno-prakticheskie napravleniya v strategii gormonal’noi terapii v posttransfernom periode [Current scientific and practical luteal phase support strategies]. Problemy reproduktsii [Problemy reprodukcii], 2016, vol. 22, no. 3, pp. 20–27.
2. Niauri D.A., Dzhemlikhanova L.Kh., Gzgzyan A.M. Reproduktivnoe zdorov’e zhenshchiny i nedostatochnost’ funktsii yaichnikov [Female reproductive health and insufficiency of ovarian function]. Zhurnal akusherstva i zhenskikh boleznei, 2010, vol. LIX, no. 1, pp. 84–90.
3. Potin V.V., Rulev V.V., Svechnikova F.A., Siklitskaya T.Yu., Kbeili X. Normogonadotropnaya pervichno-yaichnikovaya nedostatochnost’ [Normogonadotropic primary ovarian failure]. Problemy endokrinologii, 1990, vol. 36, no. 4, pp. 83–87.
4. Potin V.V. Volny gonadotropinov i diagnostika gormonal’noi nedostatochnosti yaichnikov [Waves of gonadothropins and diagnosis of hormonal ovarian insufficiency]. Zhurnal akusherstva i zhenskikh boleznei, 2004, vo. LIII, no. 1, pp. 73–78.
5. Savina V.A., Kvetnoi I.M., Kleshchev M.A., Potin V.V., Rulev V.V., Tarasova M.A., Tkachenko N.N., Yarmolinskaya M.I. Ovarian aromatase p450 in polycystic ovary syndrome. Medical academic journal, 2012, vol. 12, no. 1, pp. 66–72.
6. Savina V.A. Ovarial’naya aromataza r450 pri normogonadotropnoi nedostatochnosti yaichnikov [Ovarian aromatase р450 and normo gonadotropic ovarian deficiency]. Zhurnal akusherstva i zhenskikh boleznei, 2012, vol. LXI, no. 1, pp. 84–89.
7. Yakovlev P.P. Aktivnost’ aromatazy R450 yaichnikov v estestvennom menstrual’nom tsikle i pri stimulyatsii superovulyatsii [Aromatase P450 activity in the natural menstrual cycle and during controlled ovarian stimulation]. Zhurnal akusherstva i zhenskikh boleznei, 2017, vol. 66, no. 5, pp. 46–55. doi: 10.17816/ JOWD66546-55.
8. Yakovlev P.P., Krylova Yu.S., Mekina I.D., Polyakova V.O., Kvetnoi I.M., Tarasova M.A., Kogan I.Yu., Gzgzyan A.M., Rodichkina V.R. Aktivnost’ ovarial’noi aromatazy: metody otsenki i klinicheskoe znachenie v protokolakh ekstrakorporal’nogo oplodotvoreniya [Ovarian aromatase activity: Evaluation methods and the clinical significance in IVF protocols]. Zhurnal akusherstva i zhenskikh boleznei, 2018, vol. 67, no. 2, pp. 61–69. doi: 10.17816/JOWD67261-69.
9. Al-Inany H.G., Youssef M.A., Ayeleke R.O., Brown J., Lam W.S., Broekmans F.J. Gonadotropin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016; 4: CD001750.
10. Altmäe S., Haller K., Peters M. et al. Aromatase gene (CYP19A1) variants, female infertility and ovarian stimulation outcome: a preliminary report. Reprod Biomed Online. 2009; 18: 651–7. doi: https://doi.org/10.1016/S1472-6483(10)60009-0.
11. Balen A.H., Morley L.C., Misso M., Franks S., Legro R.S., Wijeyaratne C.N., Stener-Victorin E., Fauser B., Norman R.J., Teede H. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016; 10: 1–22.
12. Belgorosky A., Pepe C., Marino R. et al. Hypothalamic-pituitaryovarian axis during infancy, early and late prepuberty in an aromatase-deficient girl who is a compound heterocygote for two new point mutations of the CYP19 gene. J Clin Endocrinol Metabol. 2003; 88: 5127–31.
13. Berstein L.M., Imyanitov E.N., Kovalevskij A.J. et al. CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. Cancer Lett. 2004; 207: 191–6. doi: 10.1016/j.canlet.2004.01.001.
14. Broekmans F.J., Knauff E.A., Valkenburg O., Laven J.S., Eijkemans M.J., Fauser B.C. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006; 113: 1210–17.
15. Carlsson I.B., Scott J.E., Visser J.A., Ritvos O., Themmen A.P., Hovatta O. Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod. 2006; 21: 2223–7.
16. Catteau-Jonard S., Dewailly D. Pathophysiology of polycystic ovary syndrome: the role of hyperandrogenism. Front Horm Res. 2013; 40: 22–7.
17. Chen J., Shen S., Tan Y. et al. The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome. Journal of Ovarian Research. 2015; 8(1, article 11): 1–6. doi: 10.1186/s13048-015-0139-1.
18. Das M., Gillott D.J., Saridogan E., Djahanbakhch O. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Hum Reprod. 2008; 23: 2122–6.
19. Desforges-Bullet V., Gallo C., Lefebvre C., Pigny P., Dewailly D., Catteau-Jonard S. Increased anti-Mullerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization. Fertil Steril. 2010; 94: 198–204.
20. Fatemi H.M., Garcia-Velasco J. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. Fertil Steril. 2015; 103: 870–3.
21. Gabrilove J.L. The pathogenesis of the polycystic ovary syndrome: a hypothesis. Endocr Pract. 2002; 8: 127–32.
22. Heijnen E.M., Eijkemans M.J., Hughes E.G. et al. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update. 2006; 12: 13–21.
23. Jakimiuk A.J., Weitsman S.R., Brzechffa P.R., Magoffin D.A. Aromatase mRNA expression in individual follicles from polycystic ovaries. Mol Hum Reprod. 1998; 4: 1–8.
24. Kirilovas D., Chaika A., Bergström M., Bergstrom-Petterman E., Carlström K., Nosenko J. et al. Granulosa cell aromatase enzyme activity: effects of follicular fluid from patients with polycystic ovary syndrome, using aromatase conversion and [11C]vorozole-binding assays. Gynecol Endocrinol. 2006; 22: 685–91. doi: 10.1080/09513590601037535.
25. Lazaros L., Hatzi E., Xita N. et al. Aromatase (CYP19) gene variants influence ovarian response to standard gonadotrophin stimulation.  Assist Reprod Genet. 2012; 29: 203–209. doi: 10.1007/s10815-011-9673-y.
26. Leandros L., Nectaria X., Elissavet H., Atsushi T., Apostolos K., Georgios M. et al. CYP19 gene variants affect the assisted reproduction outcome of women with polycystic ovary syndrome. Gynecol Endocrinol. 2013; 29: 478–82. doi: 10.3109/09513590.2013.774359.
27. Lee H.S., Kim K.H., Hwang J.S. Association of aromatase (TTTA)n repeat polymorphisms with central precocious puberty in girls. Endocrinol (Oxf). 2014; 81(3): 395-400. doi: 10.1111/ cen.12439.
28. Li H.W., Lee V.C., Lau E.Y., Yeung W.S., Ho P.C., Ng E.H. Cumulative live-birth rate in women with polycystic ovary syndrome or isolated polycystic ovaries undergoing in-vitro fertilisation treatment. J Assist Reprod Genet. 2014; 31: 205–11.
29. Lin L., Ercan O., Raza J. et al. Variable phenotypes associated with aromatase (CYP19) insufficiency in humans. Clin. Endocrinol. Metabol. 2007; 92: 982–90.
30. McCormick B., Thomas M., Maxwell R., Williams D., Aubuchon M. Effects of polycystic ovarian syndrome on in vitro fertilizationembryo transfer outcomes are influenced by body mass index. Fertil Steril. 2008; 90: 2304–9.
31. National Collaborating Centre for Women’s and Children’s Health / National Institue for Clinical Excellence. Fertility: assessment and treatment for people with fertility problems. RCOG Press, 2004.
32. National Institute for Health and Care Excellence. Fertility: assessment and treatment for people with fertility problems. NICE guidance, 2013.
33. Nejad E.S., Saedi T., Saedi S., Rashidi B.H., Nekoo Z.A., Jahangiri N. Comparison of in vitro fertilisation success in patients with polycystic ovary syndrome and tubal factor. Gynecol Endocrinol. 2011; 27: 117–20.
34. Rowe P.J., Comhaire F.H., Hargreave T.B., Mellows H.J.WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple. Cambridge, Cambridge University Press, 1997.
35. Sahu B., Ozturk O., Ranierri M., Serhal P. Comparison of oocyte quality and intracytoplasmic sperm injection outcome in women with isolated polycystic ovaries or polycystic ovarian syndrome. Arch Gynecol Obstet. 2008; 277: 239–44.
36. Söderlund D., Canto P., Carranza-Lira S., Méndez J.P. No evidence of mutations in the P450 aromatase gene in patients with polycystic ovary syndrome. Hum Reprod. 2005; 20: 965–9.
37. Stratakis C.A., Vottero A., Brodie A. et al. The aromatase excess syndrome is associated with feminization of both sexes and autosomal dominant transmission of aberrant P450 aromatase gene transcription. J Clin Endocrinol Metabol. 1998; 83: 1348–57.
38. Weghofer A., Munne S., Chen S., Barad D., Gleicher N. Lack of association between polycystic ovary syndrome and embryonic aneuploidy. Fertil Steril. 2007; 88: 900–5.
39. Yang F., Ruan Y.C., Yang Y.J. et al. Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women. Reproduction. 2015; 150: 289–96. doi: 10.1530/REP-15-0044.